Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/148703
Title: Nanocarriers for stroke therapy : advances and obstacles in translating animal studies
Authors: Alkaff, Syed Abdullah
Radhakrishnan, Krishna
Nedumaran, Anu Maashaa
Liao, Ping
Czarny, Bertrand
Keywords: Science::Medicine
Issue Date: 2020
Source: Alkaff, S. A., Radhakrishnan, K., Nedumaran, A. M., Liao, P. & Czarny, B. (2020). Nanocarriers for stroke therapy : advances and obstacles in translating animal studies. International Journal of Nanomedicine, 15, 445-464. https://dx.doi.org/10.2147/IJN.S231853
Journal: International Journal of Nanomedicine
Abstract: The technology of drug delivery systems (DDS) has expanded into many applications, such as for treating neurological disorders. Nanoparticle DDS offer a unique strategy for targeted transport and improved outcomes of therapeutics. Stroke is likely to benefit from the emergence of this technology though clinical breakthroughs are yet to manifest. This review explores the recent advances in this field and provides insight on the trends, prospects and challenges of translating this technology to clinical application. Carriers of diverse material compositions are presented, with special focus on the surface properties and emphasis on the similarities and inconsistencies among in vivo experimental paradigms. Research attention is scattered among various nanoparticle DDS and various routes of drug administration, which expresses the lack of consistency among studies. Analysis of current literature reveals lipid- and polymer-based DDS as forerunners of DDS for stroke; however, cell membrane-derived vesicles (CMVs) possess the competitive edge due to their innate biocompatibility and superior efficacy. Conversely, inorganic and carbon-based DDS offer different functionalities as well as varied capacity for loading but suffer mainly from poor safety and general lack of investigation in this area. This review supports the existing literature by systematizing presently available data and accounting for the differences in drugs of choice, carrier types, animal models, intervention strategies and outcome parameters.
URI: https://hdl.handle.net/10356/148703
ISSN: 1176-9114
DOI: 10.2147/IJN.S231853
Rights: © 2020 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:MSE Journal Articles

Files in This Item:
File Description SizeFormat 
ijn-231853-nanocarriers-for-stroke-therapy-advances-and-obstacles-in-t.pdf1.45 MBAdobe PDFView/Open

Page view(s)

87
Updated on Jan 20, 2022

Download(s)

4
Updated on Jan 20, 2022

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.